Audiencerate Announces Its Partnership With V-Valley
Audiencerate, an innovative technology company, leader in the development of advanced solutions for digital marketing (MarTech) and online advertising (AdTech) announces that it has signed a partnership agreement with V-Valley, a company of the Esprinet Group focused on the distribution of Advanced Solutions. Thanks to its partnership with Microsoft, Audiencerate is at the forefront of integrating artificial intelligence and cloud computing to optimize marketing and advertising strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121797053/en/
Thanks to this agreement, V-Valley will make available to its resellers Audiencerate's Marketing Data Platform (MDP), one of the most advanced platforms in the sector, which - thanks to the integration of Microsoft Azure and CoPilot technologies - is able to integrate Artificial Intelligence and cloud computing, optimizing marketing campaigns and providing advanced decision-making insights. This will allow V-Valley's partners to offer their customers solutions aimed at making marketing strategies more efficient and creating more targeted marketing campaigns.
V-Valley, thanks to the specialization of its structure and its important network of partners, will support Audiencerate in the sale and growth of the Marketing Data Platform offer in Southern European companies, with a particular focus on Italy, ensuring widespread coverage and direct access to the offer.
This strategic agreement between V-Valley and Audiencerate aims to support SMEs in the process of digitalization and innovation, facilitating access to advanced technologies and contributing to their digital transformation by providing the necessary tools to compete in an increasingly data-driven market.
The V-Valley team and the Audiencerate team will collaborate to offer training and technical support to partners, ensuring a deep understanding of the potential of the MDP to end customers and its practical applications in data-driven marketing.
Marco Del Tongo, CEO of Audiencerate, stated: “Audiencerate is excited to announce the collaboration with V-Valley, a partner that shares the company's vision in terms of innovation and value creation for customers. Thanks to V-Valley's support, Audiencerate's Marketing Data Platform is now accessible to an increasingly wider audience, simplifying the adoption of advanced solutions for data management and marketing strategies. This partnership, together with the established strategic relationships with Microsoft and Google and the collaboration with vertical partners, allows Audiencerate to consolidate its role as a leader in the marketing and advertising sector, strengthening its position not only in Southern Europe but globally. Audiencerate is ready to lead the digital transformation of small and medium-sized enterprises, supporting them on their journey towards an increasingly data-driven future.”
Luca Casini, Country Manager of V-Valley in Italy, commented: “We are pleased to have entered into this new agreement with Audiencerate, thanks to which we are able to provide our partner customers with cutting-edge solutions that allow them to ride a disruptive trend such as Artificial Intelligence. All the conditions are in place to create a solid and synergistic partnership, with a positive impact on the growth and innovation of the SME market.”
Information about V-Valley
V-Valley aims to be a distributor of reference in the Advanced Solutions market, thanks to a wide range of technologies offered in on-prem and as-a-service mode, a highly specialized organization, and an extended set of services available to industry players. Enhancing your business is the payoff that summarizes the company's mission to support customers to further enhance their digital transformation projects aimed at end-user companies and Public Administration. V-Valley combines the experience of a multinational company, with the agility and knowledge of the local market, to efficiently serve its partners in a customized manner. V-Valley is a company of the Esprinet Group, a leading distributor in Southern Europe and in the top ten worldwide, listed on the Italian Stock Exchange with a turnover of 4.0 billion euros in 2023, 30,000 active customers, 800 brands in its portfolio and more than 1,800 employees.
Information about Audiencerate
Audiencerate is an innovative technology company, a leader in developing advanced solutions for digital marketing (MarTech) and online advertising (AdTech). Thanks to its partnership with Microsoft as an AI Cloud Partner and member of the ISV Success Program, Audiencerate is at the forefront of integrating artificial intelligence and cloud computing to optimize marketing and advertising strategies. In the global AdTech landscape, Audiencerate stands out as a Google Ad Technology Provider (ATP) and certified Data Provider, with a solid reputation for the reliability and quality of its solutions. Its Marketing Data Platform (MDP) is one of the most advanced in the industry, evolving the concept of Customer Data Platform (CDP) to meet data management needs securely and GDPR-compliantly, thanks to its “privacy by design” approach. With the goal of simplifying the use of data and artificial intelligence, Audiencerate supports SMEs and large companies in implementing data-driven marketing strategies, becoming the ideal partner for digital transformation and innovation in marketing operations. Its vision is to become the market reference, helping businesses navigate the increasingly complex world of advertising and marketing technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250121797053/en/
Contacts
Audiencerate Ltd
Chief Product Marketing Officer
Claudio Codispoti
Tel. +39 347 0488251
e-mail: claudio.codispoti@audiencerate.com
V-Valley
Group Communication Manager
Esprinet S.p.A
Paola Bramati
Tel. +39 02 404961
e-mail: paola.bramati@esprinet.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom